A proof of biological efficacy study assessing the potential of piboserod, a specific 5-HT4 antagonist, for the treatment of symptomatic congestive heart failure in stable outpatients (NYHA class II-IV) on top of usual evidence based pharmacological..
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 01 Dec 2006
At a glance
- Drugs Piboserod (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- 01 Dec 2006 New trial record.